New drug trial hopes to slow kidney damage in rare alport syndrome

NCT ID NCT07523581

First seen Apr 17, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This study tests a drug called exaluren in 24 people aged 12 and older with Alport syndrome caused by specific genetic mistakes. The drug aims to improve kidney structure and reduce protein in urine. Participants first receive either exaluren or a placebo for 16 weeks, then everyone gets exaluren for another 16 weeks. The goal is to see if exaluren can help control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME, X-LINKED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alder Hey Children's NHS Foundation Trust

    Liverpool, L12 2AP, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Denver Nephrologists PC, Colorado Kidney Care PC

    Denver, Colorado, 80220, United States

  • Great Ormond Street Hospital

    London, WC1N 3JH, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Royal Free Hospital

    London, NW3 2QG, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Royal Manchester Children's Hospital

    Manchester, M13 9WL, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.